Evaluation of long-term effect of tuberculosis chemoprophylaxis in patients using anti tumor necrosis factor alpha agents

Yıl 2021, Cilt: 3 Sayı: 2, 115 - 119, 24.04.2021

Şeyma Başlılar Mehtap Aydın

https://doi.org/10.38053/acmj.854759

Öz

Introduction and Aim: There is an increased risk of tuberculosis (TB) in patients with rheumatoid diseases(RD) treated with anti TNF alpha agents. Screening and, if necessary, chemoprophylaxis is recommended in patients undergoing anti TNF alpha treatment. This study aimed to determine the incidence of active TB due to long term anti TNF alpha usage in patients with RD and to evaluate the effectiveness of tuberculosis chemoprophylaxis regimen.
Materials and Methods:
Patients treated with anti TNF alpha agents for more than 5 years with RDs were evaluated retrospectively. Demographic and clinical characteristics, use of chemoprophylaxis, laboratory tests before and after anti TNF alpha treatment and development of TB were examined.
Results: A total of 150 patients (79 male [52.7%], 71 female [47.3%]) with a mean age of 45±13 years were evaluated. The tuberculosis rate over 5 years follow up was found as 1.3%. One male developed pulmonary TB 5 years and 1 female developed miliary TB 10 years after the beginning of anti-TNF alpha therapy despite chemoprophylaxis with isoniazid. The mean number of neutrophiles and lymphocytes were significantly decreased after treatment(p<0.05).
Conclusion: In an RD patient without latent TB, the risk of TB should be kept in mind even after 10 years. Regular monitoring should be considered for long term TNF antagonist therapy.

Anahtar Kelimeler

Anti TNF alpha, tuberculosis, chemoprophylaxis, long term effect

Kaynakça

• Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907– 15.
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9.
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol 2014; 41: S47‐S55.
• Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF‐α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7: e012567.
• Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti TNF-alpha treatment. Dan Med J 2012; 59: 1-12.
• Kısacık B, Pamuk ON, Onat AM, et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 2016; 43: 524-9.
• Doğan C, Kiral N, Comert SS, Fidan A, Caglayan B, Salepci B. Tuberculosis frequency in patients taking TNF alpha blockers. Turk Toraks Derg 2012; 13: 93-8.
• Aydın V, Akıcı A, Islı F, Aksoy M, Aydın M, Gürsöz H. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. J Clin Pharm Ther 2019; 44: 553-60.
• Sağlık Bakanlığı. Tüberküloz Tanı ve Tedavi Rehberi, 2. Baskı Ankara, Mayıs 2019. pp. 5-6.
• Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti TNF Therapy: Experience with 192 patients. Clin Rheumatol 2008; 27: 1083-6.
• Chan MJ, Wen YH, Huang YB, et al. Risk of tuberculosis comparison in new users of antitumour necrosis factor‐α and with existing disease‐modifying antirheumatic drug therapy. J Clin Pharm Ther 2018; 43: 256-64.
• Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-92.
• Gomez‐Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61.
• WHO. Global Tuberculosis Report 2017. Geneva, Switzerland: World Health Organization; 2017.
• Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor‐α antagonist: a meta analysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 2015; 42: 2229‐37.
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1385–97. e10.
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 1268–76.
• Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA. Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). World J Gastroenterol 2018; 24: 2764-75.
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti‐tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60: 1884‐94.
• Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 706-11.
• Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-32.
• Lee EH, Kang YA, Leem AY, et al. Active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection. Sci Rep 2017; 7: 6473.
• Nakagawa M. [Factors for the onset of and the exacerbation of tuberculosis. 4. Clinical factors related to the onset and exacerbation of tuberculosis. b. Middle-aged and elderly patients] Kekkaku. 1999; 74: 747-52.
• Jadoon SMK, Moin S, Ahmed TA, Bashir MM, Jadoon S. Smear-negative pulmonary tuberculosis and lymphocyte subsets. J Coll Physicians Surg Pak 2004; 14: 419-22.
• Berhane M,Melku M, Amsalu A, Enawgaw B, Getaneh Z. The role of neutrophil to lymphocyte count ratio in the differential diagnosis of pulmonary tuberculosis and bacterial community-acquired pneumonia: a cross-sectional study at Ayder and Mekelle Hospitals. Clin Lab 2019; 65.